Letermovir impurities are the unintended substances that may be present in commercial or laboratory-grade samples of Letermovir, a potent antiviral drug used to treat cytomegalovirus infections. These impurities can adversely affect the safety, efficacy, and stability of the drug, and therefore, their identification, characterization, and monitoring are critical to ensure the quality and purity of Letermovir formulations. Various analytical techniques, such as high-performance liquid chromatography (HPLC), mass spectrometry (MS), and nuclear magnetic resonance (NMR), are used to detect and quantify Letermovir impurities and validate the drug's compliance with regulatory standards.
